Investor Relations | Alnylam Pharmaceuticals, Inc.

Learn more about Alnylam’s response to COVID-19 ›

EVENTS & PRESENTATIONS

Oct 30, 2025 / 08:30 AM EDT

Alnylam Pharmaceuticals Q3 2025 Earnings Conference Call

Aug 12, 2025

Canaccord Genuity 45th Annual Growth Conference

Past Events ›

Jul 31, 2025

Alnylam Pharmaceuticals Q2 2025 Earnings Conference Call

Past Events ›

View all events and presentations ›

2024 Annual Report

2024 Corporate Responsibility Report

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Q2 2025 Earnings Presentation VIEW PDF ›

Latest Form 10-K VIEW PDF ›

Latest Form10-Q VIEW PDF ›

SEC
Filings VIEW All ›

2025 Proxy Statement LEARN MORE ›

View all resources and documents ›

PRESS RELEASES

Oct 16, 2025

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Oct 01, 2025

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

Sep 28, 2025

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

View all press releases ›